JCO Early Release, published online ahead of print Dec 10 2007
Journal of Clinical Oncology, 10.1200/JCO.2006.10.1022
Received November 22, 2006
Accepted June 8, 2007
Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast Cancer
Cynthia Owusu,* Diana S.M. Buist, Terry S. Field, Timothy L. Lash, Soe Soe Thwin, Ann M. Geiger, Virginia P. Quinn, Floyd Frost, Marianne Prout, Marianne Ulcickas Yood, Feifei Wei, and Rebecca A. Silliman
From the Division of Hematology/Oncology, University Hospitals of Cleveland, Cleveland, OH; Group Health Center for Health Studies, Seattle, WA; Meyers Primary Care Institute: Fallon Community Health Plan/Fallon Foundation/University of Massachusetts Medical School, Worcester; Boston University Medical Center, Boston, MA; Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC; Department of Research and Evaluation, Kaiser Permanente Medical Care Program, Pasadena, CA; Lovelace Respiratory Research Institute, Albuquerque, NM; Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT; Josephine Ford Cancer Center, Henry Ford Health System, Detroit, MI; and HealthPartners Research Foundation, Minneapolis, MN.
* To whom correspondence should be addressed. E-mail: cynthia.owusu{at}case.edu
Purpose: Five years of adjuvant tamoxifen therapy for estrogen receptor (ER) -positive breast cancer is more effective than 2 years of use. However, information on tamoxifen discontinuation is scanty. We sought to identify predictors of tamoxifen discontinuation among older women with breast cancer.
Patients and Methods: Within six health care delivery systems, we identified women  65 years old diagnosed with stage I to IIB ER-positive or indeterminant breast cancer between 1990 and 1994 who had filled a prescription for adjuvant tamoxifen. We observed them for 5 years after initial tamoxifen prescription. We used automated pharmacy records to validate tamoxifen prescription information abstracted from medical records. The primary end point was tamoxifen discontinuation, operationalized as ever discontinuing tamoxifen during 5 years of follow-up. We used Cox proportional hazards to identify predictors of tamoxifen discontinuation.
Results: Of 961 women who were prescribed tamoxifen, 49% discontinued tamoxifen before the completion of 5 years. Discontinuers were more likely to be aged 75 to less than 80 years (v < 70 years; hazard ratio [HR] = 1.41; 95% CI, 1.06 to 1.87), be aged 80 years (HR = 2.02; 95% CI, 1.53 to 2.66), have an increase in Charlson Comorbidity Index at 3 years from diagnosis (HR = 1.52; 95% CI, 1.18 to 1.95), have an increase in the number of cardiopulmonary comorbidities at 3 years (HR = 1.75; 95% CI, 1.34 to 2.28), have indeterminant ER status (v ER-positive status; HR = 1.36; 95% CI, 1.00 to 1.85), and have received breast-conserving surgery (BCS) without radiotherapy (v mastectomy; HR = 1.62; 95% CI, 1.18 to 2.22).
Conclusion: Attention to nonadherence among older women at risk of discontinuation, particularly those receiving BCS without radiotherapy, might improve breast cancer outcomes for these women.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Kimmick, R. Anderson, F. Camacho, M. Bhosle, W. Hwang, and R. Balkrishnan
Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer
J. Clin. Oncol.,
July 20, 2009;
27(21):
3445 - 3451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Ziller, M. Kalder, U.-S. Albert, W. Holzhauer, M. Ziller, U. Wagner, and P. Hadji
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ann. Onc.,
March 1, 2009;
20(3):
431 - 436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ruddy, E. Mayer, and A. Partridge
Patient adherence and persistence with oral anticancer treatment
CA Cancer J Clin,
January 1, 2009;
59(1):
56 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Yabroff, E. B. Lamont, J. L. Warren, and M. L. Brown
Response: Re: Cost of Care for the Elderly Cancer Patients in the United States
J Natl Cancer Inst,
October 1, 2008;
100(19):
1413 - 1414.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Waddell
Introduction
Am. J. Health Syst. Pharm.,
May 15, 2008;
65(10_Supplement_3):
S2 - S3.
[Full Text]
[PDF]
|
|
|
|
